Pharmacologically Active Drug Metabolites: Impact on Drug Discovery and Pharmacotherapy

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmacological Reviews

• Publication date

  2013-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/pr.111.005439PMID 23406671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Propoxyphene.

  2020cited by this paper
• Clobazam

  2013cited by this paper
• Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?

  2012cited by this paper
• Astemizole

  2012cited by this paper
• Prediction of Relative In Vivo Metabolite Exposure from In Vitro Data Using Two Model Drugs: Dextromethorphan and Omeprazole

  2012cited by this paper
• Dabigatran

  2012cited by this paper
• CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.

  2012cited by this paper
• Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC-MS/MS.

  2012cited by this paper
• A Review of its Pharmacology and Therapeutic Potential in the Management of Nausea and Vomiting Induced by Chemotherapy, Radiotherapy or Surgery

  2012cited by this paper
• Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.

  2012cited by this paper
• A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.

  2012cited by this paper
• Why do metabolites circulate?

  2012cited by this paper
• Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients

  2011cited by this paper
• Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

  2011cited by this paper
• A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.

  2011cited by this paper
• Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency

  2011cited by this paper
• Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin.

  2011cited by this paper
• Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration

  2011cited by this paper
• Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs.

  2011cited by this paper
• Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR

  2011cited by this paper
• Desbutyl-Lumefantrine Is a Metabolite of Lumefantrine with Potent In Vitro Antimalarial Activity That May Influence Artemether-Lumefantrine Treatment Outcome

  2011cited by this paper
• In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.

  2011cited by this paper
• CYP3AP1*3 Allele Is Associated With Lipid‐Lowering Efficacy of Simvastatin and Atorvastatin in Chinese Women

  2011cited by this paper
• Macitentan: entry-into-humans study with a new endothelin receptor antagonist

  2011cited by this paper
• Itraconazole and Rifampin Alter Significantly the Disposition and Antihistamine Effect of Ebastine and Its Metabolites in Healthy Participants

  2010cited by this paper
• Quantification of the major metabolites of bromhexine in human plasma using RRLC-MS/MS and its application to pharmacokinetics.

  2010cited by this paper
• Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

  2010cited by this paper
• Toward Biophysical Probes for the 5-HT3 Receptor: Structure−Activity Relationship Study of Granisetron Derivatives

  2010cited by this paper
• Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters

  2010cited by this paper
• Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice.

  2010cited by this paper
• Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein.

  2010cited by this paper
• Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites.

  2010cited by this paper
• Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development.

  2010cited by this paper
• Dabigatran Acylglucuronide, the Major Human Metabolite of Dabigatran: In Vitro Formation, Stability, and Pharmacological Activity

  2010cited by this paper
• Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

  2010cited by this paper
• Drug–drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice

  2010cited by this paper
• CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases

  2009cited by this paper
• The Targeted Oral, Once‐Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions

  2009cited by this paper
• Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.

  2009cited by this paper
• Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites.

  2009cited by this paper
• Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.

  2009cited by this paper
• Carisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo Studies

  2009cited by this paper
• Clinical pharmacology of camptothecins

  2009cited by this paper
• Serum Concentrations of Antidepressant Drugs in a Naturalistic Setting: Compilation Based on a Large Therapeutic Drug Monitoring Database

  2009cited by this paper
• A High-Throughput Ligand Competition Binding Assay for the Androgen Receptor and Other Nuclear Receptors

  2009cited by this paper
• Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects

  2009cited by this paper
• Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

  2009cited by this paper
• The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.

  2009cited by this paper
• Impact of pH on plasma protein binding in equilibrium dialysis.

  2008cited by this paper
• The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans

  2008cited by this paper
• Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

  2008cited by this paper
• Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects

  2008cited by this paper
• Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function.

  2008cited by this paper
• Ebastine in allergic rhinitis and chronic idiopathic urticaria

  2008cited by this paper
• CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

  2008cited by this paper
• Relationship between Antimalarial Activity and Heme Alkylation for Spiro- and Dispiro-1,2,4-Trioxolane Antimalarials

  2008cited by this paper
• An improved HPLC method for rapid quantitation of diazepam and its major metabolites in human plasma.

  2008cited by this paper
• Quantitation of donepezil and its active metabolite 6-O-desmethyl donepezil in human plasma by a selective and sensitive liquid chromatography-tandem mass spectrometric method.

  2008cited by this paper
• Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine.

  2008cited by this paper
• Ambroxol in the 21st century: pharmacological and clinical update.

  2008influential reference
• No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.

  2008cited by this paper
• Metabolism and Disposition of Dasatinib after Oral Administration to Humans

  2008cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol

  2007cited by this paper
• Roflumilast inhibits leukocyte‐endothelial cell interactions, expression of adhesion molecules and microvascular permeability

  2007cited by this paper
• Pharmacokinetics and Pharmacodynamics of Once‐Daily Controlled‐Release Oxybutynin and Immediate‐Release Oxybutynin

  2007cited by this paper
• Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram.

  2007cited by this paper
• Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication

  2007cited by this paper
• Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo

  2007cited by this paper
• Analytical strategies for identifying drug metabolites.

  2007cited by this paper
• Dopamine and Serotonin Receptor Binding and Antipsychotic Efficacy

  2007cited by this paper
• ADME Studies in Animals and Humans: Experimental Design, Metabolite Profiling and Identification, and Data Presentation

  2007cited by this paper
• 6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats

  2007cited by this paper
• Consensus statements, evidence‐based medicine and guidelines in allergic diseases

  2007cited by this paper
• Praziquantel derivatives I: Modification of the aromatic ring.

  2007cited by this paper
• CYP2C9 variant modifies blood pressure‐lowering response to losartan in Type 1 diabetic patients with nephropathy

  2007cited by this paper
• A review of the immunosuppressive activity of cyclosporine metabolites: new insights into an old issue.

  2007cited by this paper
• Levosimendan: beyond its simple inotropic effect in heart failure.

  2007cited by this paper
• Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor

  2006cited by this paper
• Rapid on-line profiling of estrogen receptor binding metabolites of tamoxifen.

  2006cited by this paper
• Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.

  2006cited by this paper
• Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents

  2006cited by this paper
• Role of pharmacologically active metabolites in drug discovery and development.

  2006cited by this paper
• Pharmacokinetic Variability of Aripiprazole and the Active Metabolite Dehydroaripiprazole in Psychiatric Patients

  2006cited by this paper
• Nonlinear kinetics of propafenone metabolites in healthy man

  2006cited by this paper
• Oxcarbazepine

  2006cited by this paper
• Biochemical characterization of some pyrazolopyrimidine-based inhibitors of xanthine oxidase

  2006cited by this paper
• Pharmacokinetics of a Newly Identified Active Metabolite of Buspirone After Administration of Buspirone Over Its Therapeutic Dose Range

  2006cited by this paper
• Morphine‐6‐glucuronide: Actions and mechanisms

  2005cited by this paper
• Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects

  2005cited by this paper
• P‐glycoprotein interaction with risperidone and 9‐OH‐risperidone studied in vitro, in knock‐out mice and in drug–drug interaction experiments

  2005cited by this paper
• Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist

  2005cited by this paper
• Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Disposition of desloratadine in healthy volunteers

  2005cited by this paper
• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

  2005cited by this paper
• Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.

  2005cited by this paper
• Clinical Pharmacokinetics of Imatinib

  2005cited by this paper
• CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

  2005cited by this paper
• Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

  2005cited by this paper
• Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.

  2005cited by this paper
• Buprenorphine

  2005cited by this paper

• Photodegradation of typical psychotropic drugs in the aquatic environment: a critical review.

  2025cites this paper
• Halogenated Curcumin Derivatives: SwissADME/ADMT, DFT and Biological Targets Prediction

  2025cites this paper
• Causal proteomic insights into drug target discovery for tension-type headache

  2025cites this paper
• Metabolite Identification Data in Drug Discovery, Part 1: Data Generation and Trend Analysis

  2025cites this paper
• Pharmacokinetic variability of 20(S)-protopanaxadiol-type ginsenosides Rb1, rd, and compound K from Korean red ginseng in experimental rodents

  2025cites this paper
• Safety pharmacology of sibutramine analogues evaluated by in silico and in vitro biological target screening.

  2025cites this paper
• Baeyer-Villiger monooxygenase immobilized on magnetic nanoparticles: reusable biocatalytic system for drug metabolite synthesis.

  2025cites this paper
• In vivo assessment of the role of liver metabolism in sydnone imine biotransformation

  2025cites this paper
• Recent advances in traditional Chinese medicine metabolism: Sample pre-treatment, MS-oriented analytical strategies and typical applications

  2025cites this paper
• Characterization of Ten Novel Metabolites of a PAF Antagonist SY0916 in Rats Using LC-MS and NMR

  2025cites this paper
• Small molecule drug metabolite synthesis and identification: why, when and how?

  2024cites this paper
• The Current State of Biotransformation Science – Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future Trends

  2024cites this paper
• Proteome-wide Mendelian randomization identified potential drug targets for migraine

  2024cites this paper
• In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives

  2024cites this paper
• Protein Haptenation and Its Role in Allergy

  2024cites this paper
• Atherosclerosis, gut microbiome, and exercise in a meta-omics perspective: a literature review

  2024cites this paper
• Biocatalysis using Thermostable Cytochrome P450 Enzymes in Bacterial Membranes – Comparison of Metabolic Pathways with Human Liver Microsomes and Recombinant Human Enzymes

  2024cites this paper
• Biotransformation of antioxidant eriocitrin into characteristic metabolites by the gut microbiota

  2023cites this paper
• Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group

  2023cites this paper
• MetaTox 2.0: Estimating the Biological Activity Spectra of Drug-like Compounds Taking into Account Probable Biotransformations

  2023cites this paper
• INTEDE 2.0: the metabolic roadmap of drugs

  2023cites this paper
• A Review on Epigenetic Toxicological Mechanisms of Sildenafil and Its Metabolites, the Emerging Pollutants

  2023cites this paper
• Consideration of Nevirapine Analogs To Reduce Metabolically Linked Hepatotoxicity: A Cautionary Tale of the Deuteration Approach

  2023cites this paper
• Importance and review of drug metabolite synthesis

  2023cites this paper
• Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α2-adrenoceptor and trace amine-associated receptor 1 ligand

  2023cites this paper
• Utilizing mechanistic organic chemistry training to study drug metabolism in preclinical drug discovery/development

  2023cites this paper
• One-pot Double Oxidation Synthesis of N-1-Piperidonyl Amides From N-1-Piperidinyl Amides with mCPBA: Rimonabant Analogue as Model Study.

  2023cites this paper
• Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA‐approved targeted small molecule oncology drugs

  2023cites this paper
• In Vivo Metabolite Profiling of DMU-212 in ApcMin/+ Mice Using UHPLC-Q/Orbitrap/LTQ MS

  2023cites this paper
• Computational pharmacology and computational chemistry of 4-hydroxyisoleucine: Physicochemical, pharmacokinetic, and DFT-based approaches

  2023cites this paper
• Molecular basis of the different effects of procainamide and N-acetylprocainamide on the maximum upstroke velocity and half-decay time of the cardiac action potential in guinea pig papillary muscle

  2023cites this paper
• Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance

  2023cites this paper
• Structural Investigation of Betulinic Acid Plasma Metabolites by Tandem Mass Spectrometry

  2022cites this paper
• Drug Metabolite Cluster Centers-based Strategy for Comprehensive Profiling of Neomangiferin Metabolites in vivo and in vitro and Network Pharmacology Study on Anti-inflammatory Mechanism

  2022cites this paper
• The potential impact of a probiotic: Akkermansia muciniphila in the regulation of blood pressure—the current facts and evidence

  2022cites this paper
• A brief review on critical analytical aspects for quantification of ambroxol in biological samples.

  2022cites this paper
• Library Screening for Synergistic Combinations of FDA-Approved Drugs and Metabolites with Vancomycin against VanA-Type Vancomycin-Resistant Enterococcus faecium

  2022cites this paper
• Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates

  2022cites this paper
• A metabolomics study of the intervention effect of Tartary buckwheat on hyperlipidemia mice.

  2022cites this paper
• Biotransformation novel advances – 2021 year in review

  2022cites this paper
• Determination of Daphnetin and its 8-O-Methylated Metabolite in Rat Plasma by UFLC-MS/MS: Application to a Pharmacokinetic Study

  2022cites this paper
• Toxicity and toxicokinetic considerations in product development and drug research

  2022cites this paper
• Design and molecular insights of drug-active metabolite based co-amorphous formulation: a case study of toltrazuril-ponazuril co-amorphous.

  2022cites this paper
• A simple LC-MS/MS method for the simultaneous quantification of drug metabolic enzymes.

  2022cites this paper
• Medical Treatment in Men with Infertility Can Be Misinterpreted as Doping Practice: A Case of Unintentional World Anti-Doping Agency (WADA) Code Violation

  2022cites this paper
• Related substances method development and validation of an LCMS/MS method for quantification of selexipag and its related impurities in rat plasma and its application to pharmacokinetic studies

  2021cites this paper
• Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications

  2021cites this paper
• Identifying Metabolites of Diphenidol by Liquid Chromatography-Quadrupole/Orbitrap Mass Spectrometry Using Rat Liver Microsomes, Human Blood and Urine Samples.

  2021cites this paper
• A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases.

  2021cites this paper
• Analysis of gut microbiota in patients with epilepsy treated with valproate: Results from a three months observational prospective cohort study.

  2021cites this paper
• Evaluation of amentoflavone metabolites on PARP-1 inhibition and the potentiation on anti-proliferative effects of carboplatin in A549 cells.

  2021cites this paper
• DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING RELATED SUBSTANCES OF TRANDOLAPRIL BY RP-HPLC AND ITS DEGRADATION

  2021cites this paper
• Development and Validation of Analytical HPLC-UV Method for simultaneous estimation of Losartan and its active Metabolite EXP-3174

  2021cites this paper
• Identification, Synthesis, and Characterization of a Major Circulating Human Metabolite of TRPV4 Antagonist GSK2798745.

  2021cites this paper
• Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 1. Theoretical Considerations

  2021cites this paper
• High resolution mass spectrometry-based approach for the identification and profiling of the metabolites of taletrectinib formed in liver microsomes.

  2021cites this paper
• Complex Cytochrome P450 Kinetics Due to Multisubstrate Binding and Sequential Metabolism. Part 2. Modeling of Experimental Data

  2021cites this paper
• Protective Property of Scutellarin Against Liver Injury Induced by Carbon Tetrachloride in Mice

  2021cites this paper
• Biologically active metabolites in drug discovery.

  2021cites this paper
• A Study of the Identification, Fragmentation Mode and Metabolic Pathways of Imatinib in Rats Using UHPLC-Q-TOF-MS/MS

  2021cites this paper
• Preclinical metabolic characterization of mefunidone, a novel anti-renal fibrosis drug.

  2021cites this paper
• Comprehensive genome based analysis of Vibrio parahaemolyticus for identifying novel drug and vaccine molecules: Subtractive proteomics and vaccinomics approach

  2020cites this paper
• Metabolic profiles of Ribociclib in rat and human liver microsomes by using liquid chromatography combined with electrospray ionization high resolution mass spectrometry.

  2020cites this paper
• Drug Metabolite Identification using UHPLC UV Spectroscopy and Parallelized Scans on a Tribrid Orbitrap Mass Spectrometer.

  2020cites this paper
• Transforming of Triptolide into Characteristic Metabolites by the Gut Microbiota

  2020cites this paper
• Efficient multiresidue determination method for 168 pharmaceuticals and metabolites: Optimization and application to raw wastewater, wastewater effluent, and surface water in Beijing, China.

  2020cites this paper
• THE EFFECTIVE APPLICATION OF METABOLITE PROFILING IN DRUG DESIGN AND DISCOVERY.

  2020cites this paper
• Structure Elucidation of Urinary Metabolites of Fentanyl and Five Fentanyl Analogs using LC-QTOF-MS, Hepatocyte Incubations and Synthesized Reference Standards

  2020cites this paper
• Does In Vitro Potency Predict Clinically Efficacious Concentrations?

  2020cites this paper
• Metabolism and Pharmacokinetics of SP-8356, a Novel (1S)-(−)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans

  2020cites this paper
• Novel propanolamine derivatives attached to 2-metoxifenol moiety: Synthesis, characterization, biological properties, and molecular docking studies.

  2020cites this paper
• Mini‐Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study

  2020cites this paper
• In vitro metabolic characterization of orbitazine, a novel derivative of the PAC-1 anticancer agent.

  2020cites this paper
• Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.

  2020cites this paper
• Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges

  2020cites this paper
• Computer-Aided Estimation of Biological Activity Profiles of Drug-Like Compounds Taking into Account Their Metabolism in Human Body

  2020cites this paper
• Drug Metabolites: General Features and Most Applicable Analytical Methods of Studies

  2020cites this paper
• Substrate recognition of renally eliminated angiotensin II receptor blockers by organic anion transporter 4.

  2020cites this paper
• Methods for metabolite generation and characterization by NMR

  2020cites this paper
• High-resolution mass spectrometry-based data acquisition and data-mining technologies for detecting and characterizing drug metabolites and traditional Chinese medicine components

  2020cites this paper
• Human Efflux Transporters in Drug Disposition : in vitro Transport of Glucuronide Metabolites

  2019cites this paper
• LC-QTOF-MS Identification of Major Urinary Cyclopropylfentanyl Metabolites Using Synthesized Standards

  2019cites this paper
• Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human

  2019cites this paper
• Mapping human microbiome drug metabolism by gut bacteria and their genes

  2019cites this paper
• Establishment of rat liver microsome-hydrogel system for in vitro phase II metabolism and its application to study pharmacological effects of UGT substrates.

  2019cites this paper
• Dimensionally Enhanced Antibacterial Library Screening.

  2019cites this paper
• Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application

  2019cites this paper
• Structural characterization, immune regulation and antioxidant activity of a new heteropolysaccharide from Cantharellus cibarius Fr.

  2018cites this paper
• Pharmacokinetic-pharmacodynamic correlations in the development of ginger extract as an anticancer agent

  2018cites this paper
• Aliphatic C-H Oxidations for Late-Stage Functionalization.

  2018cites this paper
• Combined Iron/Hydroxytriazole Dual Catalytic System for Site Selective Oxidation Adjacent to Azaheterocycles.

  2018cites this paper
• Combination of experimental and in silico methods for the assessment of the phototransformation products of the antipsychotic drug/metabolite Mesoridazine.

  2018cites this paper
• Zeolite encapsulated host-guest Cu(II) Schiff base complexes: Superior activity towards oxidation reactions over homogenous catalytic systems

  2018cites this paper
• The Role of Transporters in Drug Accumulation and Mitochondrial Toxicity

  2018cites this paper
• Towards Understanding the Phenytoin-like Antiepileptic Effect of Cannabidiol and Related Phytocannabinoid Metabolites: Insights from Molecular Modeling

  2018cites this paper
• Understanding the pharmacokinetics of prodrug and metabolite

  2018cites this paper
• Chemoselective methylene oxidation in aromatic molecules

  2018cites this paper
• Synthesis of oxidative metabolites of CRA13 and their analogs: Identification of CRA13 active metabolites and analogs thereof with selective CB2R affinity.

  2018cites this paper
• In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone 
Metabolites of Albendazole, Triclabendazole, Aldicarb, Methiocarb, Montelukast and Ziprasidone

  2018influential citation
• Pharmacokinetic, metabolic profiling and elimination of brusatol in rats.

  2018cites this paper